Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1959 1
1960 1
1961 3
1963 1
1964 3
1965 2
1966 1
1967 4
1968 3
1969 2
1970 5
1971 4
1972 1
1973 1
1975 2
1976 2
1977 2
1978 5
1980 3
1981 1
1982 3
1983 5
1984 7
1985 10
1986 17
1987 8
1988 8
1989 7
1990 3
1991 8
1992 3
1993 3
1994 4
1995 4
1996 3
1997 1
1998 8
1999 8
2000 8
2001 10
2002 8
2003 14
2004 11
2005 11
2006 23
2007 18
2008 22
2009 18
2010 19
2011 32
2012 25
2013 30
2014 23
2015 30
2016 38
2017 46
2018 34
2019 41
2020 57
2021 38
Text availability
Article attribute
Article type
Publication date

Search Results

646 results
Results by year
Filters applied: . Clear all
Page 1
Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
Tamiya M, Tamiya A, Suzuki H, Moriizumi K, Nakahama K, Taniguchi Y, Kunimasa K, Kimura M, Inoue T, Kuhara H, Nishino K, Hirashima T, Atagi S, Imamura F, Kumagai T. Tamiya M, et al. Among authors: nishino k. Anticancer Res. 2019 Jul;39(7):3923-3929. doi: 10.21873/anticanres.13544. Anticancer Res. 2019. PMID: 31262922
Multiplex gene-panel testing for lung cancer patients.
Yatabe Y, Sunami K, Goto K, Nishio K, Aragane N, Ikeda S, Inoue A, Kinoshita I, Kimura H, Sakamoto T, Satouchi M, Shimizu J, Tsuta K, Toyooka S, Nishino K, Hatanaka Y, Matsumoto S, Mikubo M, Yokose T, Dosaka-Akita H. Yatabe Y, et al. Among authors: nishino k. Pathol Int. 2020 Dec;70(12):921-931. doi: 10.1111/pin.13023. Epub 2020 Sep 21. Pathol Int. 2020. PMID: 32956529 Review.
Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L).
Seto T, Azuma K, Yamanaka T, Sugawara S, Yoshioka H, Wakuda K, Atagi S, Iwamoto Y, Hayashi H, Okamoto I, Saka H, Mitsuoka S, Fujimoto D, Nishino K, Horiike A, Daga H, Sone T, Yamamoto N, Nakagawa K, Nakanishi Y. Seto T, et al. Among authors: nishino k. J Clin Oncol. 2020 Mar 10;38(8):793-803. doi: 10.1200/JCO.19.01494. Epub 2019 Dec 27. J Clin Oncol. 2020. PMID: 31880966 Clinical Trial.
Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
Sugiyama T, Okamoto A, Enomoto T, Hamano T, Aotani E, Terao Y, Suzuki N, Mikami M, Yaegashi N, Kato K, Yoshikawa H, Yokoyama Y, Tanabe H, Nishino K, Nomura H, Kim JW, Kim BG, Pignata S, Alexandre J, Green J, Isonishi S, Terauchi F, Fujiwara K, Aoki D. Sugiyama T, et al. Among authors: nishino k. J Clin Oncol. 2016 Aug 20;34(24):2881-7. doi: 10.1200/JCO.2016.66.9010. Epub 2016 Jul 11. J Clin Oncol. 2016. PMID: 27400948 Clinical Trial.
XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary.
Tamura R, Yoshihara K, Nakaoka H, Yachida N, Yamaguchi M, Suda K, Ishiguro T, Nishino K, Ichikawa H, Homma K, Kikuchi A, Ueda Y, Takei Y, Fujiwara H, Motoyama T, Okuda S, Wakai T, Inoue I, Enomoto T. Tamura R, et al. Among authors: nishino k. Oncogene. 2020 Apr;39(17):3541-3554. doi: 10.1038/s41388-020-1237-0. Epub 2020 Mar 2. Oncogene. 2020. PMID: 32115573 Free PMC article.
Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L).
Kato R, Hayashi H, Chiba Y, Miyawaki E, Shimizu J, Ozaki T, Fujimoto D, Toyozawa R, Nakamura A, Kozuki T, Tanaka K, Teraoka S, Usui K, Nishino K, Hataji O, Ota K, Ebi N, Saeki S, Akazawa Y, Okuno M, Yamamoto N, Nakagawa K. Kato R, et al. Among authors: nishino k. J Immunother Cancer. 2020 Feb;8(1):e000350. doi: 10.1136/jitc-2019-000350. J Immunother Cancer. 2020. PMID: 32066647 Free PMC article.
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
Akamatsu H, Toi Y, Hayashi H, Fujimoto D, Tachihara M, Furuya N, Otani S, Shimizu J, Katakami N, Azuma K, Miura N, Nishino K, Hara S, Teraoka S, Morita S, Nakagawa K, Yamamoto N. Akamatsu H, et al. Among authors: nishino k. JAMA Oncol. 2021 Mar 1;7(3):386-394. doi: 10.1001/jamaoncol.2020.6758. JAMA Oncol. 2021. PMID: 33410885 Free PMC article.
Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study).
Shimizu J, Masago K, Saito H, Nishino K, Kurata T, Itoh Y, Yoshimura Y, Yabuki Y, Dosaka-Akita H. Shimizu J, et al. Among authors: nishino k. Ther Adv Med Oncol. 2020 Feb 22;12:1758835920904522. doi: 10.1177/1758835920904522. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32127924 Free PMC article.
646 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page